JAMA Cardiology

JAMA Cardiology JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed publications

In a US cohort, higher systolic genetic risk was associated with new-onset after pregnancy, but elevated postpartum ...
04/02/2026

In a US cohort, higher systolic genetic risk was associated with new-onset after pregnancy, but elevated postpartum body mass index and hypertensive disorders of pregnancy were stronger risk factors.

https://ja.ma/4bZtO9T

💬 Editorial: Among patients with in the Veterans Health Administration, fewer than 1 in 6 achieved quadruple therapy a...
04/01/2026

💬 Editorial: Among patients with in the Veterans Health Administration, fewer than 1 in 6 achieved quadruple therapy and the median time to initiation exceeded 6 months.

https://ja.ma/41Js93u

Among US veterans with with reduced ejection fraction, fewer than one-quarter achieved quadruple guideline-directed me...
04/01/2026

Among US veterans with with reduced ejection fraction, fewer than one-quarter achieved quadruple guideline-directed medical therapy within 2.9 years, and medication copays were associated with lower rates of therapy achievement.

https://ja.ma/4bZZpIA

In the open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous treatment with acoramidi...
03/30/2026

In the open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous treatment with acoramidis in patients with transthyretin amyloid cardiomyopathy ( ) resulted in durable reductions in all-cause and cardiovascular mortality, as well as first cardiovascular hospitalization, through 54 months.

Continuous acoramidis stabilized NT-proBNP and functional outcomes (6-minute walk distance and Kansas City Cardiomyopathy Questionnaire), while biomarker improvements and clinical stability were also observed in patients switched from placebo to acoramidis. No new long-term safety concerns were identified.



https://ja.ma/4uZoCf1

In a large contemporary cohort from the iSCAD Registry, women with pregnancy-associated spontaneous coronary artery diss...
03/29/2026

In a large contemporary cohort from the iSCAD Registry, women with pregnancy-associated spontaneous coronary artery dissection ( ) exhibited distinctive reproductive and clinical features compared with those with nonpregnancy-associated SCAD ( ). was associated with higher rates of assisted reproductive technology use, preeclampsia, and multigravidity, and occurred at older maternal ages than in the general population.

Clinically, women with PSCAD had a more severe presentation—including higher rates of STEMI, multivessel involvement, and acute left ventricular dysfunction—with less left ventricular recovery by 1-year follow-up, though most were managed conservatively.



https://ja.ma/4uX51Mx

Among patients with provoked who completed initial anticoagulation and had enduring risk factors, extended low-dose ap...
03/29/2026

Among patients with provoked who completed initial anticoagulation and had enduring risk factors, extended low-dose apixaban reduced symptomatic superficial vein thrombosis events compared with placebo, with a primary outcome hazard ratio of 0.30.

Most SuVT cases were symptomatic, required unanticipated clinical evaluation, and frequently led to additional anticoagulation, highlighting the clinical relevance of prevention.

These exploratory findings support further investigation in larger studies dedicated to SuVT.



https://ja.ma/4bCYOh9

In a prospective cohort of patients with atrial fibrillation ( ), higher serum neurofilament light chain ( ) concentrati...
03/29/2026

In a prospective cohort of patients with atrial fibrillation ( ), higher serum neurofilament light chain ( ) concentrations measured at baseline were independently associated with increased risk of major vascular events—including cardiovascular death, nonfatal stroke, heart failure–related hospitalization, and all-cause mortality—over a median follow-up of 8 years.

The association between sNfL and cardiovascular outcomes persisted after adjustment for comorbidities and cardiovascular biomarkers. These findings suggest sNfL may serve as a prognostic biomarker beyond traditional risk factors in AF populations.



https://ja.ma/40W5uRr

📊 JAMA Clinical Guidelines Synopsis: The 2025 ACC/AHA guideline recommends home and office monitoring to confirm diagn...
03/29/2026

📊 JAMA Clinical Guidelines Synopsis: The 2025 ACC/AHA guideline recommends home and office monitoring to confirm diagnosis and titrate medications, with a target blood pressure of

💬 Editorial by JAMA Senior Editor Philip Greenland, MD, and Donald M. Lloyd-Jones, MD, MSc: guidelines have expanded t...
03/28/2026

💬 Editorial by JAMA Senior Editor Philip Greenland, MD, and Donald M. Lloyd-Jones, MD, MSc:

guidelines have expanded to include earlier and broader use of statins for prevention, but many patients do not reach LDL-C targets on maximally tolerated therapy.

The VESALIUS-CV trial found that evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced major cardiovascular events in high-risk primary prevention patients—with particularly strong evidence among those with long-standing .

Cost, long-term safety, and optimal use in lower-risk groups remain areas for further study.



https://ja.ma/4bPuChB

From JAMA: 📊 Research Summary: Among adults with high-risk and elevated LDL cholesterol but no significant atheroscler...
03/28/2026

From JAMA:

📊 Research Summary: Among adults with high-risk and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events.

https://ja.ma/4bHTNCA

From JAMA: In the VESALIUS-CV trial, adults with high-risk but without known significant atherosclerosis experienced a...
03/28/2026

From JAMA: In the VESALIUS-CV trial, adults with high-risk but without known significant atherosclerosis experienced a lower risk of first major adverse cardiovascular events when evolocumab, a proprotein convertase subtilisin/kexin type 9 ( ) inhibitor, was added to statin therapy.

The primary outcomes—coronary heart disease death, myocardial infarction, or ischemic stroke—were reduced, and effect estimates were consistent across baseline risk factors. Rates of all-cause and cardiovascular mortality were also lower with evolocumab.

Results support intensification of LDL cholesterol lowering in high-risk primary prevention patients with diabetes, but broader generalizability requires further evaluation.



https://ja.ma/3NJSNGm

💬 Editor's Note by JAMA Cardiology Associate Editor Gregg C. Fonarow, MD: A post hoc analysis of the FINEARTS-HF trial ...
03/28/2026

💬 Editor's Note by JAMA Cardiology Associate Editor Gregg C. Fonarow, MD: A post hoc analysis of the FINEARTS-HF trial examined clinical and biomarker trajectories preceding sudden death in patients with with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).

Modest but detectable functional and symptom deterioration, as well as rising natriuretic peptide levels, were noted in the months before sudden death, but changes were similar to those preceding non-sudden fatal outcomes.

Dynamic clinical worsening often occurs before sudden death, yet lacks specificity for risk stratification, highlighting the need for more refined predictive tools.



https://ja.ma/4dfjP2I

Address

330 N Wabash Avenue
Chicago, IL
60611

Telephone

+13126707827

Website

Alerts

Be the first to know and let us send you an email when JAMA Cardiology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category